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Transforming growth factor beta (TGF-,), a multifunctional cytokine and growth factor, plays a key
role in scarring and fibrotic processes because of its ability to induce extracellular matrix proteins
and modulate the growth and immune function of many cell types. These effects are important in
inflammatory disorders with fibrosis and cancer. The asbestos-related diseases are characterized
by fibrosis in the lower respiratory tract and pleura and increased occurrence of lung cancer and
mesothelioma. We performed immunohistochemistry with isoform-specific antibodies to the
three TGF-3 isoforms on 16 autopsy lungs from Quebec, Canada, asbestos miners and millers.
There was increased immunolocalization of all three TGF-B isoforms in the fibrotic lesions of
asbestosis and pleural fibrosis. The hyperplastic type 11 pneumocytes contained all three isoforms.
By contrast, there was differential spatial immunostaining for the TGF-, isoforms in malignant
mesothelioma, with TGF-,1 in the stroma but TGF-P2 in the tumor cells. These data are
consistent with an important role for TGF-0 in accumulation of extracellular matrix and cell
proliferation in asbestos-related diseases. - Environ Health Perspect 105(Suppl 5):1197-1203
(1997)
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Introduction
Transforming growth factor beta (TGF-P)
is a multifunctional cytokine that enhances
extracellular matrix formation, inhibits cel-
lular proliferation, and suppresses immune
processes (1,2). The three TGF-P mam-
malian isoforms (TGF-p1, TGF-P2, and
TGF-P3) have a different distribution and
function in vivo (3,4). A variety of onco-
genes includingjun,fos, and ras upregulate
TGF-1I through activator protein-I bind-
ing sites on the promoter (5). The
retinoblastoma gene product activates
TGF-P2 gene expression by stimulating
nuclear proteins that bind to the promoter
(6). TGF-f1 enhances expression ofextra-
cellular matrix components including
fibronectin, av,1l fibronectin receptor, col-
lagen, and decorin, aTGF-f31 binding pro-
teoglycan (1,7,8). Furthermore, TGF-1
inhibits metalloproteinases and stimulates
protease inhibitors, which contributes to
matrix accumulation (9).
Extracellular matrix accumulation is the
hallmark of asbestos-related pulmonary
and pleural fibrosis and some types of
malignant mesothelioma (10). Increased
amounts of collagen deposit in alveolar
walls and terminal respiratory bronchioles,
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near the pleural lymphatics (plaque forma-
tion), and in the stroma of mesothelioma,
where thick collagen fibers are intermixed
with tumor cells. Therefore, we propose
that TGF-1 may be present to stimulate
collagen production. We previously
showed that TGF-,1, -42, and -43 are
intensely localized to extracellular matrix
zones of early and developing fibrotic
lesions in the lungs ofsheep treated intra-
tracheally with chrysotile asbestos (11). In
the nodular lesions ofsilicosis, we reported
that central hyalinized areas showed the
maximum immunostaining for TGF-4
(12). In acute silicosis, we observed marked
staining ofhyperplastic alveolar epithelium,
as well as intense staining of alveolar
macrophage(s) (AM). In this study we
hypothesized that TGF-,B would promote
matrix accumulation in asbestosis, pleural
plaques, and mesothelioma, and that the
TGF-,B isoforms may have differential roles
in this process.
Methods
StudyPopulation
Autopsy lung tissue from 16 individuals
exposed to chrysotile asbestos in the mines
and mills in Thetford, Quebec, Canada,
were evaluated. Autopsies were performed
as part of the Quebec Workers' Com-
pensation Board inquiries. Subjects were
71 ±8 years old (mean ± SD) at the time of
death and had worked for 38± 5 years in
the asbestos industry. A review of their
work histories revealed that all had signifi-
cant chrysotile exposure, and that none
had worked in areas where there may have
been crocidolite exposures. All had histo-
logic evidence ofpulmonary fibrosis. Five
individuals also had lung carcinoma and
four had malignant mesothelioma. All
study subjects were male and all had a his-
tory ofcigarette smoking. There were two
control autopsies from individuals killed in
traffic accidents. (These were both smokers
who smoked 36 and 48 pack-years, respec-
tively). The control lungs had no histologic
evidence ofpulmonary fibrosis.
Antibodies
The isoform-specific antibodies to
TGF-,B1, -p2, and -13 were previously
described and characterized (13). Briefly,
peptides ofeach TGF-,3 isoform were syn-
thesized using a 430A peptide synthesizer
(Applied Biosystems, Foster City, CA).
The following amino acid residues were
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used: TGF-[B1 and -[2, residues 4 to 19;
TGF-[B3, residues 9 to 20. The peptides
were coupled to keyhole limpet hemo-
cyanin prior to injection. Each rabbit
polyclonal antiserum was purified by pep-
tide affinity chromatography and was
shown by Western blot analysis to be spe-
cific for the corresponding mature TGF-[
isoform and noncross-reactive with the
other TGF-[ isoforms (13). The antibod-
ies recognize both the latent and active
forms ofTGF-[ isoforms; because TGF-[
exists as a latent molecule, the epitopes on
the mature molecule are available.
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Paraffin sections (5 pim) were incubated in
tris-buffered saline ([TBS] 0.01 M Tris,
0.15 M NaCl, pH 7.4)/0.3% Triton X-
100 for 15 min; TBS for 5 min; absolute
methanol for 2 min; and methanol/0.6%
hydrogen peroxide (v/v) for 30 min to
quench endogenous peroxidase. The slides
were then rinsed briefly in methanol, fol-
lowed by three washes in TBS/0.1% (wt/v)
bovine serum albumin (BSA) for 5 min
each. The sections were treated with hya-
luronidase (1 mg/ml in 100 mM sodium
acetate buffer, pH 5.5, with 0.85% [wt/v]
NaCl) for 30 min at 370C, then rinsed
three times in TBS/0.1% BSA. Nonspecific
protein staining was blocked by 1.5% goat
serum for 20 min. The sections were incu-
bated overnight at 4°C with 100 to 200 ml
ofprimary antibody to final concentration
of 2.5 mg/ml in- blocking solution. The
sections were rinsed at room temperature
with TBS and incubated with biotinylated
goat antirabbit immunoglobulin for 1 hr
in a humid staining box at room temper-
ature (Elite Vectastain Kit, Vector
Laboratories, Burlingame, CA). After
extensive washes, the sections were incu-
bated with avidin-biotin-peroxidase com-
plex for 1 hr at room temperature and
developed according to the manufacturer's
recommendations. The slides were coun-
terstained with Gill's hematoxylin #2 and
viewed under alight microscope.
Results
Immunohistochemical Llizaton
ofTGF-P Isoforms inAsbestosis
TGF-, isoform-specific antibodies applied
to sections of lung from two unexposed
controls demonstrated the minimal pres-
ence ofTGF-41, -42, and -[3 in bronchi,
bronchiolar epithelium, AM, bronchial
and vascular smooth muscle, but not in
cartilage or immune cells. There were no
Figure 1. Control lung (TGF-I81). TGF-,1l immunostaining is detected in macrophages (M), smooth muscle cells
(SM), and bronchial epithelial cells(Epi). Magnification x100.
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Figure 2. Control lung(TGF-J32).TGF-P2 immunostaining with M, SM, and Epi identified. Magnification x400.
consistent differences in the staining
pattern of each isoform (Figures 1 to 3,
TGF-1, -42, and-43, respectively). The
presence of all isoforms in control lungs
suggests a physiologic role for TGF-[B in
normal tissue homeostasis. No immuno-
staining was detected in fibrotic lung
sections using nonimmune sera or saline
followed bysecondary antibody.
In contrast, fibrotic lungs demonstrated
intense staining for all three TGF-,B iso-
forms in the extracellular matrix or early
peribronchial fibrosis and in metaplastic
proliferating epithelium of far advanced
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Figure 3. Control lung (TGF-03). TGF-J3 immunostaining is noted in Epi and SM. Anthracotic pigment is also
noted. Magnification x400.
Figure 4. Asbestosis. TGF-)1 immunostaining of hyperplastic type 11 pneumocytes (arrows) and extracellular
matrix in thickened alveolarwalls. Magnification x10.
lesions ofhoneycomb lung. In contrast to
normal lung, fibrotic peribronchiolar
lesions had intense immunostaining for all
three isoforms in type II pneumocytes,
smooth muscle cells, and macrophages
(Figure 4). The TGF-i1 immunostaining
increased in these cells with an increase in
the number ofthese cells per unit area. In
the advanced lesions characterized by
honeycombing and marked architectural
derangement, all three TGF-, isoforms
were detected in hyperplastic type II
pneumocytes and epithelial cells that lined
cystic spaces (Figure 5). The extracellular
matrix within fibrotic areas demonstrated
intense immunostaining for all three TGF-
f isoforms (Figure 5). Pleural plaque is
characteristically a basket-weave pattern of
collagen fibrils. All three TGF-3 isoforms
stained the matrix in the pleural fibrosis
intensely (Figure 6).
Immunohistochemical Localization
ofTGF-[ Isoforms
inMalignantMesothelioma
Three distinct spatial distributions for the
TGF-P isoforms were observed. TGF-,1
immunostaining was detected in the des-
moplastic extracellular matrix between
mesothelial cells of mesothelioma (Figure
7). Stromal cells stained more intensely
for TGF-P2 than TGF-1l, and staining
of the tumor cells was markedly less
(Figure 8). TGF-P3 was detected in the
stroma, and manyofthe tumor cells stained
positively (Figure 9).
Discussion
We used immunohistochemistry to
demonstrate TGF-1 isoform staining in
fibrotic lesions of asbestosis and pleural
plaques in autopsy samples of Quebec
chrysotile miners and millers. All three
antibodies toTGF-P isoforms stained early
peribronchiolar fibrosis as well as bronchial
epithelial cells, AM, and smooth muscle
cells. As the fibrosis progressed, TGF-P
isoform immunoreactivity markedly
increased parallel to the increase of extra-
cellular matrix, reactive hyperplastic type II
pneumocytes, and macrophages. Normal
lungs had minimal TGF-P immuno-
staining but immunostaining was present
in the same lung structures (e.g., macro-
phages and bronchial epithelial cells), and
we previously demonstrated no staining
with nonimmune sera (11). In malignant
mesothelioma, TGF-31 localized more to
the stroma, whereas TGF-P2 localized
more to the mesothelioma cells than to the
stroma. TGF-P3 had minimal immunos-
taining ofboth stroma and mesothelioma
cells. These results suggest that TGF-, iso-
forms are important for the accumulation
ofextracellular matrix in asbestosis, pleural
fibrosis, and malignant mesothelioma.
In the bleomycin rat model, AM
produced TGF-i1 after 7 days. This
TGF-P1 subsequently increased 5 to 6-fold,
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Figure 5. Advanced lesion of honeycomb lung. TGF-03 was intense in the extracellular matrix of fibrotic areas.
Immunostaining was prominent in alveolar macrophages (open arrow). Significant anthracotic pigment was also
present. Closed arrow, type 11 pneumocytes. Magnification x6.5.
Figure 6. Pleural plaque. TGF-)1 immunostaining of collagen fibrils in parietal pleural plaque. Magnification
x4O0.
constituting 50 to 77% of total TGF-,B.
Isoforms TGF-i2 and -,B3 remained
unchanged (14,15). Santana and col-
leagues found that all three mammalian
TGF-P isoforms increased in the acutely
injured areas in the same rat pulmonary
fibrosis model, with prominent staining of
macrophages, parenchymal cells, bronchial
epithelium, and type II pneumocytes (3).
Infusion ofanti-TGF-P1 antibody in the
tail vein in the murine bleomycin model
significantly reduced lung collagen at 14
days, which provided direct evidence for
the presence of TGF-3 as a cause of
collagen overproduction in the fibrotic
process (16). Zhang et al. noted that
TGF-, mRNA and protein peaked from
days 3 to 14 in eosinophils, myofibroblasts,
and fibroblasts, with fibroblasts in fibrotic
areas prominent thereafter (17). There was
discordance in bronchiolar epithelial cells,
with strong protein expression unaccompa-
nied by a commensurate increase in mRNA
(16,17). TGF-P stimulates fibroblasts to
synthesize collagen and fibronectin, and
stimulates smooth muscle cells to synthesize
elastin (18). In addition, it promotes extra-
cellular matrix accumulation by decreasing
collagenase synthesis and increasing the
production ofprotease inhibitors such as
tissue inhibitor of metalloproteinase and
plasminogen activator inhibitor-1 (9,19).
TGF-P also modulates the expression of
receptors for matrix proteins involved in
cell-cell and cell-matrix adhesion (20).
We demonstrated TGF-, isoform
immunostaining in the peribronchiolar
fibrotic lesions in a sheep model ofasbesto-
sis (11). Interestingly, insulinlike growth
factor-I (IGF-I) immunolocalization was
noted in fibroblasts at the periphery ofthe
fibrotic lesions, which was consistent with a
IGF-I complementary role in the stimula-
tion offibroblast proliferation. TGF-] was
localized to fibrotic regions and bronchial
epithelial cells. In agreement with our
studies, a rat model ofearly asbestosis local-
izedTGF-P1 in AM and in alveolar epithe-
lial cells at alveolar septal tips (21). TGF-P
paracrine/autocrine action was postulated
to contribute to fibronectin deposition near
these sites (21).
TGF-P immunostaining was also
intense in the rounded nodular lesions of
silicosis (12). In human idiopathic pul-
monary fibrosis (IPF), bronchiolar epithelial
cells, macrophages, and type II pneumo-
cytes contained abundant TGF-,B mRNA
and protein (22-24). Khalil and colleagues
(25) studied TGF-P isoforms in IPF and
observed that TGF-P1 was present in
macrophages, epithelial cells, and extracel-
lular matrix in advanced lesions, whereas
TGF-PI was present only in macrophages,
not epithelial cells, in early lesions. They
conduded thatTGF-P2 andTGF-P3 were
ubiquitously expressed in the lung, and
that TGF-pl was an indication of the
chronic lung injury. Two ofthe study's 12
patients had asbestosis; TGF-P staining
was noted in bronchiolar epithelial cells,
epithelial cells lining honeycomb cysts,
AM, and fibrous connective tissue in the
interstitium. The alveolar type II epithelium
constitutes at least the main reservoir, if
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Figure 7. Malignant mesothelioma. TGF-,B1 immunostaining was detected in the stroma of mesothelioma where thick collagen fibers contain clefts lined with tumor cells.
Magnification x10.
Figure 8. Malignant mesothelioma. Mesothelioma cells were not immunostained forTGF-]2. Extensive immunostaining was detected in the stroma. Magnification xl10.
not the site ofsynthesis, for TGF-P1 and
tumor necrosis factor alpha (26). TGF-P
immunostaining was largely found in the
matrix, which is consistent with recent
reports indicating thatTGF-P is converted
from a latent to an active molecule while
bound to the extracellular matrix by the
latent TGF-f binding protein (27).
Both TGF-e2 and -[3 immunolocalized
to mesothelioma cells. TGF-j3 has been
measured in the pleural fluid from meso-
thelioma patients and was three to six times
higher than in primary lung cancer patients
(28). TGF-f has a growth inhibitory effect
in the GI phase ofthe cell cycle (29). The
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Figure 9. Malignant mesothelioma. TGF-p3 was detected both in stromal elements and mesothelioma cells. Magnification x25.
growth inhibitory effect is mediated
through cyclins and cyclin-dependent
kinases. TGF-4 inhibitory effects may be
mediated through two different families
of cell-cycle inhibitors. First, TGF-,B in-
duced p15 activity 30-fold in human
keratinocytes, and p15 blocks cyclin-
dependent kinases (CDK)4 and CDK6,
which bind cyclin D early in the Gi phase
(30). Second, TGF-, induces p21
(WAF1/Cipl), which acts as a cell-cycle
checkpoint late in Gl by inhibiting CDK2
complexes with cyclin E (31). TGF-P sup-
presses phosphorylation of retinoblastoma
(Rb) protein, favoring formation ofa com-
plex between Rb/E2F that blocks cells
from moving beyond the GI restriction
point (6). The protein product ofRb can
transcriptionally activate the TGF-,1 and -
,B2 genes, which may be a novel mecha-
nism for constraining cellular proliferation
(5). TGF-P also suppresses c-myc, which
functions, at least in part, in the early half
of Gl as a progression factor (32). Both
jun andfos are transcription factors that
activate the TGF-P1 promoter, and
asbestos exposure upregulatesjun andfos
mRNA in rat pleural mesothelial cells
within 4 hr (33). Other cytokines, includ-
ing IL-6, growth factor IGF-I, and platelet-
derived growth factor, have autocrine
growth regulatory loops in mesothelioma
(34,35). The role ofTGF-0 in malignant
mesothelioma may be to inhibit the cell
proliferation that is consistent with the
bulkiness and lack of metastases by this
tumor, and to enhance stroma. TGF-,B iso-
forms are induced in asbestos-related dis-
eases and are associated with extracellular
matrix in asbestosis, pleural fibrosis, and
malignant mesothelioma.
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